NCT00333086|CompletedPhase 2
A Study of Letrozole in the Treatment of Endometrial Cancer
A PHASE II STUDY OF LETROZOLE IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Loading search results
A PHASE II STUDY OF LETROZOLE IN PATIENTS WITH ADVANCED OR RECURRENT ENDOMETRIAL CANCER
Sponsor study identifier
interventional
36
1 country
1
Study Start
January 2000
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
June 2006
Actual (reported)Study Completion
Not reported
Date not reportedCurrently available treatments for endometrial cancer are associated with limited efficacy and significant toxicity. This study will assess the safety and efficacy of letrozole, an aromatase inhibitor, on endometrial cancer.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
January 2000
Date type not reportedThis date has not been verified as actual or estimated.
June 2006
Actual (reported)June 1, 2006
Actual (reported)June 2, 2006
Actual (reported)Response rates (complete response, partial response, no change, progressive disease) measured by tumor marker assessments and radiologic imaging at week 12 then every 12 weeks x 1 year followed by every 16 weeks
Duration of clinical response, time to progression of the disease, correlation of tumor response with pretreatment ER/PR status, histological grade and aromatase levels
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Novartis Investigative Site
Heidelberg, Germany
Novartis Pharmaceuticals
Novartis Pharmaceuticals
36 participants (actual enrollment reported by the registry).
First Submitted
June 1, 2006
First Posted
June 2, 2006
Study Start
January 2000
Date type not reportedThis date has not been verified as actual or estimated.
Study of Safety and Efficacy of Letrozole Monotherapy as Second-line Endocrine Therapy in Postmenopausal Patients With Advanced Breast Cancer Who Received Previous Anti-estrogen Treatment
Contact the study team to confirm eligibility.
Primary Completion
June 2006
Actual (reported)Last Updated
April 19, 2012
Record last verified: 2012-04
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: